The predictive performance of the baseline IFNγ-associated gene signature for differentiating ICI response achieved an AUC of 0.69 in a mixed cohort of stage III melanoma patients with and without adjuvant therapy [29] and an AUC of 0.67 in stage III melanoma patients receiving neoadjuvant ICI therapy [10]. Here, IFNG is linked to melanoma.